避妊薬市場：タイプ別、剤形別、作用機序別、材料タイプ別、使用期間別、使用頻度別、販売チャネル別、用途別、エンドユーザー別-2025～2030年世界予測

避妊薬市場の2024年の市場規模は384億米ドルで、2025年には411億3,000万米ドル、CAGR7.41%で成長し、2030年には589億8,000万米ドルに達すると予測されています。

避妊薬市場は、科学技術の進歩や消費者の嗜好の変化により、力強い革新とダイナミックな進化の時代を迎えています。近年、市場参入企業は、より効果的で便利かつ柔軟な避妊ソリューションへの需要の高まりを特徴とする環境を乗り越えてきました。この変革は、進化する医療施策、リプロダクティブヘルスに関する意識の高まり、研究開発への多額の投資によって支えられています。企業や利害関係者は現在、患者中心のアプローチを優先する戦略を採用しており、その結果、従来の方法が変革的なブレークスルーによって継続的に強化される状況が醸成されています。

このような環境では、情報に基づいた意思決定と戦略的計画が極めて重要な役割を果たします。今日の市場は、技術の進歩だけでなく、消費者の導入に影響を与える社会経済的な変化によっても左右されます。主要利害関係者が技術革新とアクセシビリティのバランスを取ろうと努力する中、世界市場は拡大を続け、成長と協力のための有望な機会を提供しています。こうした側面を分析することは、避妊薬産業を形成する要因の広範な影響を理解するための基盤となります。こ概要は、より詳細な洞察、戦略的シフト、徹底的な市場分析に不可欠なセグメンテーション力学について論じるための舞台を整えるものです。

避妊薬市場の変革

最近の市場における変革的なシフトは、避妊の認識、開発、提供方法を再定義しています。製品技術の革新、個人のニーズの重視の高まり、製品配合の画期的な進歩はすべて、従来の方法からより多様なソリューションへのシフトに寄与しています。主要企業は現在、長期的な信頼性と短期的な柔軟性の両方のニーズに応えるため、剤形を最適化し送達メカニズムを改善する先端研究に投資しています。

さらに、規制の変更と医療の枠組みの進化により、製品開発サイクルが大幅に早まっています。品質管理の強化や臨床効果の重視は、消費者の信頼を高めています。市場動向は、オンライン流通チャネルが情報や製品へのアクセスを拡大し、最終的に顧客エンゲージメントの向上につながるなど、デジタルアウトリーチへの顕著な軸足を示しています。こうしたダイナミックな変化は、市場がもはや停滞することなく、常にイノベーションを受け入れていることを示しています。この継続的な進化は、さらなる成長と製品提供の洗練のための舞台を整えつつあり、ますますダイナミックになる市場で競合を維持するためには、産業リーダーにとって戦略を適応させ、軸足を移すことが不可欠となっています。

主要セグメンテーション洞察

様々なセグメンテーションアプローチを通じて市場を分析することは、消費者行動を理解し、ニッチな機会を特定するための貴重な視点を記載しています。市場はタイプ別に調査され、緊急避妊薬、ホルモン剤、非ホルモン剤、永久避妊法などの分析が行われます。緊急避妊薬では、IUDとピルの両方が注目され、ホルモン剤では、インプラント、注射、経口、経皮避妊薬に細かく分類されています。非ホルモン性カテゴリーをさらに調査すると、バリア法、ハーブ避妊薬、自然な方法についての詳細な洞察が得られ、ハーブのカテゴリーはアーユルヴェーダとホメオパシーのアプローチに細分化されています。一方、永続的なセグメントでは、卵管結紮とパイプカットの選択肢が特徴的です。

その他の次元としては、製品の剤形があり、パッチ、ピル、リングなどの形態で分析され、ピルについてはさらに一相性と多相性のサブタイプが調査されます。多角的な視点を採用することで、市場は作用機序によっても調査され、着床防止、殺精子作用、排卵抑制などのソリューションが区別されます。さらに、ラテックスベースと非ラテックスのバリエーションを評価することで、材料タイプに焦点を当てた洞察も行っています。後者については、ニトリル、ポリイソプレン、ポリウレタンをさらに調査しています。期間ベースのセグメンテーションでは、製品を長期と短期のソリューションに分け、使用頻度では、オンデマンドソリューションと通常使用を区別しています。流通チャネルと用途シナリオは、このセグメンテーションをさらに細分化し、病院薬局や伝統的薬局などのオフラインの場と、eコマースポータルやオンライン薬局などのオンラインプラットフォームの両方を通じての流通を分析します。最後に、エンドユーザー分析では、市場を女性層と男性層に区分し、女性層はさらに思春期、成人、閉経後のグループに分類し、消費者層と嗜好に関する包括的な展望を提供しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • リプロダクティブヘルスと避妊に関する消費者の意識と教育の向上
    • 人口管理のための避妊具の使用を促進する政府の取り組みと施策
    • より新しく、より効果的な避妊薬方法の開発につながる技術の進歩
  • 抑制要因
    • 効果的な避妊薬手法に関する教育と意識向上で遭遇する障壁
  • 機会
    • 遠隔医療の増加により、遠隔地や忙しい消費者が処方箋にアクセスしやすくなる
    • 男性用避妊薬への注目が高まることで、製品の革新と多様化の新たな機会が生まれる
  • 課題
    • 多様なニーズを満たす避妊薬ソリューションにおけるパーソナライゼーションとカスタマイズの懸念
    • 避妊薬の受容と採用に影響を与える社会的・文化的偏見への対処
• 市場セグメンテーション分析
  • タイプ：効果と中止の容易さから経口避妊薬への傾向が高い
  • エンドユーザー：幅広い製品が利用できるため、女性用避妊具の採用が大幅に増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 避妊薬市場：タイプ別

• イントロダクション
• 緊急避妊薬
  • 子宮内避妊器具
  • 錠剤
• ホルモン
  • 埋め込み型避妊具
  • 注射避妊薬
  • 経口避妊薬
  • 経皮避妊薬
• 非ホルモン性
  • バリア法
  • ハーブ避妊薬
    • アーユルヴェーダ
    • ホメオパシー
  • 自然な方法
• 永続
  • 卵管結紮術
  • 精管切除術

第7章 避妊薬市場：剤形別

• イントロダクション
• パッチ
• ピル
  • 単相性
  • 多相性
• 指輪

第8章 避妊薬市場：作用機序別

• イントロダクション
• 着床防止
• 殺精子作用
• 排卵抑制

第9章 避妊薬市場：材料タイプ別

• イントロダクション
• ラテックスベース
• ラテックス不使用
  • ニトリル
  • ポリイソプレン
  • ポリウレタン

第10章 避妊薬市場：使用期間別

• イントロダクション
• 長期
• 短期

第11章 避妊薬市場：使用頻度別

• イントロダクション
• オンデマンド
• 通常使用

第12章 避妊薬市場：流通チャネル別

• イントロダクション
• オフライン
  • 病院薬局
  • 薬局
• オンライン
  • eコマースプラットフォーム
  • オンライン薬局

第13章 避妊薬市場：用途別

• イントロダクション
• 一般用途
• 性交後の使用

第14章 避妊薬市場：エンドユーザー別

• イントロダクション
• 女性
  • 思春期
  • 成人用
  • 閉経後
• 男性

第15章 南北アメリカの避妊薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第16章 アジア太平洋の避妊薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第17章 欧州・中東・アフリカの避妊薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第18章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbvie Inc.
• Acme Generics Pvt. Ltd.
• Afaxys, Inc.
• Agile Therapeutics, Inc.
• Amneal Pharmaceuticals LLC
• ASKA Pharmaceutical Co., Ltd.
• Aurobindo Pharma Limited
• Bayer AG
• Church & Dwight Co., Inc.
• Cipla Limited
• HLL Lifecare Limited
• Insud Pharma, S.L.
• Johnson & Johnson Services, Inc.
• Lupin Limited
• Mayne Pharma Group Limited
• Merck & Co., Inc.
• Mithra Pharmaceuticals S.A.
• Okamoto Industries, Inc.
• Organon & Co.
• Perrigo Company PLC
• Pfizer Inc.
• Piramal Pharma Ltd.
• Reckitt Benckiser Group PLC
• Ritex GmbH
• Sanofi S.A.
• Say It With A Condom, LLC
• Syzygy Healthcare Solutions LLC
• Teva Pharmaceutical Industries Ltd.
• TherapeuticsMD, Inc.
• TTK Healthcare Limited
• Veru Inc.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. CONTRACEPTIVE MARKET MULTI-CURRENCY
• FIGURE 2. CONTRACEPTIVE MARKET MULTI-LANGUAGE
• FIGURE 3. CONTRACEPTIVE MARKET RESEARCH PROCESS
• FIGURE 4. CONTRACEPTIVE MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
• FIGURE 21. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 23. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 25. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. AMERICAS CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. AMERICAS CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 29. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 30. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 31. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 32. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 33. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 34. CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 35. CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CONTRACEPTIVE MARKET DYNAMICS
• TABLE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 68. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 69. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 70. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 71. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 72. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 75. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 76. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 77. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 78. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 79. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 80. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 81. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 82. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 83. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 84. AMERICAS CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 85. AMERICAS CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 86. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. AMERICAS CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 88. AMERICAS CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 89. AMERICAS CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. AMERICAS CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 92. AMERICAS CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 93. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 95. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 96. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 97. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 98. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 99. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 100. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 101. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 102. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 104. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 105. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 106. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 108. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 109. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. ARGENTINA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 112. BRAZIL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. BRAZIL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 114. BRAZIL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 115. BRAZIL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 116. BRAZIL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 117. BRAZIL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 118. BRAZIL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 119. BRAZIL CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 120. BRAZIL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 121. BRAZIL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 122. BRAZIL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 123. BRAZIL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 124. BRAZIL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 125. BRAZIL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. BRAZIL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 127. BRAZIL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 128. BRAZIL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. BRAZIL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. BRAZIL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 131. CANADA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. CANADA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 133. CANADA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 134. CANADA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 135. CANADA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 136. CANADA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 137. CANADA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 138. CANADA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 139. CANADA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 140. CANADA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 141. CANADA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 142. CANADA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 143. CANADA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 144. CANADA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. CANADA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 146. CANADA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 147. CANADA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. CANADA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. CANADA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 150. MEXICO CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. MEXICO CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 152. MEXICO CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 153. MEXICO CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 154. MEXICO CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 155. MEXICO CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 156. MEXICO CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 157. MEXICO CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 158. MEXICO CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 159. MEXICO CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 160. MEXICO CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 161. MEXICO CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 162. MEXICO CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 163. MEXICO CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. MEXICO CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 165. MEXICO CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 166. MEXICO CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. MEXICO CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. MEXICO CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 169. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 171. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 172. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 173. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 174. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 175. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 176. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 177. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 178. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 179. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 180. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 181. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 182. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED STATES CONTRACEPTIVE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 191. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 192. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 193. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 194. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 195. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 196. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 197. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 198. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 199. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 200. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 201. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 202. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 203. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 204. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 205. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 208. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 209. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 211. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 212. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 213. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 214. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 215. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 216. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 217. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 218. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 219. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 220. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 221. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 222. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 224. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 225. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. AUSTRALIA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 228. CHINA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. CHINA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 230. CHINA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 231. CHINA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 232. CHINA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 233. CHINA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 234. CHINA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 235. CHINA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 236. CHINA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 237. CHINA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 238. CHINA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 239. CHINA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 240. CHINA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 241. CHINA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. CHINA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 243. CHINA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 244. CHINA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. CHINA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 246. CHINA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 247. INDIA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 248. INDIA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 249. INDIA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 250. INDIA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 251. INDIA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 252. INDIA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 253. INDIA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 254. INDIA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 255. INDIA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 256. INDIA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 257. INDIA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 258. INDIA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 259. INDIA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 260. INDIA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. INDIA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 262. INDIA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 263. INDIA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. INDIA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 265. INDIA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 266. INDONESIA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 267. INDONESIA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 268. INDONESIA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 269. INDONESIA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 270. INDONESIA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 271. INDONESIA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 272. INDONESIA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 273. INDONESIA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 274. INDONESIA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 275. INDONESIA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 276. INDONESIA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 277. INDONESIA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 278. INDONESIA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 279. INDONESIA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 280. INDONESIA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 281. INDONESIA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 282. INDONESIA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. INDONESIA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. INDONESIA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 285. JAPAN CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 286. JAPAN CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 287. JAPAN CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 288. JAPAN CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 289. JAPAN CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 290. JAPAN CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 291. JAPAN CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 292. JAPAN CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 293. JAPAN CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 294. JAPAN CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 295. JAPAN CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 296. JAPAN CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 297. JAPAN CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 298. JAPAN CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 299. JAPAN CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 300. JAPAN CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 301. JAPAN CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 302. JAPAN CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 303. JAPAN CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 304. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 305. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 306. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 307. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 308. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 309. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 310. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 311. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 312. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 313. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 314. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 315. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 316. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 317. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 318. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 319. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 320. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 321. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 322. MALAYSIA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 323. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 324. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 325. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 326. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 327. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 328. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 329. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 330. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 331. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 332. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 333. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 334. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 335. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 336. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 337. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 338. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 339. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 340. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 341. PHILIPPINES CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 342. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 343. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 344. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 345. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 346. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 347. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 348. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 349. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 350. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 351. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 352. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 353. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 354. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 355. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 356. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 357. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2030 (USD MILLION)
• TABLE 358. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 359. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 360. SINGAPORE CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2030 (USD MILLION)
• TABLE 361. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 362. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 363. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2030 (USD MILLION)
• TABLE 364. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2030 (USD MILLION)
• TABLE 365. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
• TABLE 366. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2030 (USD MILLION)
• TABLE 367. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 368. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2030 (USD MILLION)
• TABLE 369. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 370. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
• TABLE 371. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2030 (USD MILLION)
• TABLE 372. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2030 (USD MILLION)
• TABLE 373. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2030 (USD MILLION)
• TABLE 374. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 375. SOUTH KOREA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2

The Contraceptive Market was valued at USD 38.40 billion in 2024 and is projected to grow to USD 41.13 billion in 2025, with a CAGR of 7.41%, reaching USD 58.98 billion by 2030.

The contraceptive market is witnessing an era of robust innovation and dynamic evolution, driven by advances in science, technology, and shifting consumer preferences. In recent years, market participants have navigated an environment characterized by increasing demand for more effective, convenient, and flexible contraceptive solutions. This transformation is underpinned by evolving healthcare policies, rising awareness regarding reproductive health, and significant investments in research and development. Companies and stakeholders are now adopting strategies that prioritize patient-centric approaches, thereby fostering a landscape where traditional methods are continuously enhanced by transformative breakthroughs.

In this environment, informed decision-making and strategic planning play pivotal roles. The market today is not only determined by technological advancements but also by the socio-economic shifts that influence consumer adoption. As key stakeholders strive to balance innovation with accessibility, the global market continues to expand, offering promising opportunities for growth and collaboration. Analyzing these aspects provides the foundation for understanding the extensive impact of factors shaping the contraceptive industry. This overview sets the stage to discuss more detailed insights, strategic shifts, and segmentation dynamics pivotal to a thorough market analysis.

Transformative Shifts in the Contraceptive Landscape

Recent transformative shifts in the market have redefined how contraception is perceived, developed, and delivered. Innovations in product technology, increased emphasis on individual needs, and breakthroughs in product formulations have all contributed to a shift from conventional methods to more diversified solutions. Key players are now investing in advanced research to optimize dosage formations and improve delivery mechanisms, catering to the need for both long-term reliability and short-term flexibility.

Additionally, regulatory changes and evolving healthcare frameworks have significantly accelerated product development cycles. Enhanced quality control measures and an emphasis on clinical efficacy have bolstered consumer confidence. Market trends indicate a notable pivot towards digital outreach, with online sales channels expanding access to information and products, ultimately leading to improved customer engagement. These dynamic changes are indicative of a market that is no longer stagnant but is constantly embracing innovation. This ongoing evolution is setting the stage for further growth and refinement in product offerings, making it imperative for industry leaders to adapt and pivot their strategies in order to remain competitive in an increasingly dynamic market.

Key Segmentation Insights

Analyzing the market through various segmentation approaches provides invaluable perspectives for understanding consumer behavior and identifying niche opportunities. The market is studied based on type, where the analysis spans the spectrum of Emergency Contraceptives, Hormonal, Non-Hormonal, and Permanent methods. In emergency applications, both IUDs and Pills receive distinct attention, while the hormonal segment is meticulously dissected into Implantable, Injectable, Oral, and Transdermal Contraceptives. Further exploration within the non-hormonal category reveals detailed insights into Barrier Methods, Herbal Contraceptives, and Natural Methods, with the herbal category subdivided into Ayurvedic and Homeopathic approaches. The permanent segment, on the other hand, is characterized by Tubal Ligation and Vasectomy options.

Other dimensions include the formulation of products, which are analyzed in forms such as Patch, Pill, and Ring, with a further investigation into Monophasic and Multiphasic subtypes for pills. By adopting a multi-dimensional perspective, the market is also examined according to mode of action, distinguishing solutions that prevent implantation, enact spermicidal action, or suppress ovulation. Additional insights focus on material type by evaluating Latex-Based and Non-Latex variants; the latter is further studied across Nitrile, Polyisoprene, and Polyurethane. Duration-based segmentation divides products into long-term and short-term solutions, while usage frequency differentiates on-demand solutions from regular use. Sales channels and application scenarios further refine this segmentation, with distribution analyzed through both offline venues including hospital pharmacy and traditional pharmacy, and online platforms such as e-commerce portals and online pharmacies. Lastly, end-user analysis segments the market into female and male demographics, with the female segment further classified by adolescent, adult, and post-menopausal groups, offering a comprehensive outlook on consumer demographics and preferences.

Based on Type, market is studied across Emergency Contraceptives, Hormonal, Non-Hormonal, and Permanent. The Emergency Contraceptives is further studied across IUDs and Pills. The Hormonal is further studied across Implantable Contraceptives, Injectable Contraceptives, Oral Contraceptives, and Transdermal Contraceptives. The Non-Hormonal is further studied across Barrier Methods, Herbal Contraceptives, and Natural Methods. The Herbal Contraceptives is further studied across Ayurvedic and Homeopathic. The Permanent is further studied across Tubal Ligation and Vasectomy.

Based on Formulation, market is studied across Patch, Pill, and Ring. The Pill is further studied across Monophasic and Multiphasic.

Based on Mode Of Action, market is studied across Prevent Implantation, Spermicidal Action, and Suppress Ovulation.

Based on Material Type, market is studied across Latex-Based and Non-Latex. The Non-Latex is further studied across Nitrile, Polyisoprene, and Polyurethane.

Based on Duration, market is studied across Long-Term and Short-Term.

Based on Usage Frequency, market is studied across On-Demand and Regular Use.

Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Pharmacy. The Online is further studied across E-Commerce Platforms and Online Pharmacy.

Based on Application, market is studied across General Use and Post-Coital Use.

Based on End-User, market is studied across Female and Male. The Female is further studied across Adolescent, Adult, and Post-Menopausal.

Key Regional Insights

Geographic analysis reveals compelling trends that suggest a broad array of opportunities across multiple regions. In the Americas, market growth is supported by a combination of robust healthcare infrastructure and significant investment in pharmaceutical research, driving rapid adoption and diversification of contraceptive products. Regulatory frameworks in this region facilitate easy market entry while also promoting innovation through supportive public health reforms. Similarly, the expansive territory of Europe, the Middle East, and Africa presents a diverse landscape where mature markets coexist with burgeoning economies that are increasingly prioritizing reproductive health. The integration of digital technologies into traditional healthcare systems is fostering a reimagined approach to distribution and customer engagement across these regions.

In addition to these, the Asia-Pacific region emerges as a notable hotspot of growth. Factors such as a rising middle-class population, improved healthcare access, and governmental initiatives aiming to enhance public awareness contribute to an accelerated demand for both conventional and innovative contraceptive solutions. Cross-regional comparisons highlight that while the Americas benefit from strategic investments and established health services, Europe, the Middle East, and Africa are demonstrating agility through policy reforms and market liberalization. The Asia-Pacific, meanwhile, remains a strategic target for expansion given its dynamic consumer base and rapid technological adaptation. These insights collectively underscore the importance of tailoring market strategies to specific regional characteristics in order to optimize reach and impact.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

An analysis of the market is incomplete without a thorough understanding of the influential companies driving growth and innovation. Leading industry players such as Abbvie Inc. have consistently demonstrated a commitment to research excellence and product innovation. Acme Generics Pvt. Ltd. and Afaxys, Inc. contribute significantly to competitive pricing strategies, while firms like Agile Therapeutics, Inc. and Amneal Pharmaceuticals LLC push boundaries in product accessibility. Domestic and international collaborations by ASKA Pharmaceutical Co., Ltd. and Aurobindo Pharma Limited have paved the way for broader market penetration across varied demographics.

Companies including Bayer AG, Church & Dwight Co., Inc., and Cipla Limited continue to invest in market diversification and adaptation to regulatory standards, ensuring that their product pipelines remain robust and responsive to consumer needs. HLL Lifecare Limited and Insud Pharma, S.L. have strategically focused on expanding their geographic presence, while Johnson & Johnson Services, Inc. and Lupin Limited emphasize quality and customer reliability. Global leaders such as Mayne Pharma Group Limited, Merck & Co., Inc., and Mithra Pharmaceuticals S.A. are setting industry benchmarks, with additional insights provided by firms like Okamoto Industries, Inc., Organon & Co., and Perrigo Company PLC. The competitive landscape is further enriched by market powerhouses including Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group PLC, Ritex GmbH, Sanofi S.A., and emerging innovators like Say It With A Condom, LLC, Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc. collectively shaping the future of the contraceptive market.

The report delves into recent significant developments in the Contraceptive Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Acme Generics Pvt. Ltd., Afaxys, Inc., Agile Therapeutics, Inc., Amneal Pharmaceuticals LLC, ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Bayer AG, Church & Dwight Co., Inc., Cipla Limited, HLL Lifecare Limited, Insud Pharma, S.L., Johnson & Johnson Services, Inc., Lupin Limited, Mayne Pharma Group Limited, Merck & Co., Inc., Mithra Pharmaceuticals S.A., Okamoto Industries, Inc., Organon & Co., Perrigo Company PLC, Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group PLC, Ritex GmbH, Sanofi S.A., Say It With A Condom, LLC, Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to harness the potential of emerging trends and strategic segmentation to secure a competitive advantage in the dynamic contraceptive market. A data-driven approach is paramount-one that harnesses robust market intelligence to identify and prioritize under-served segments. Companies should invest in developing innovative products that align with shifting consumer demographics, particularly by focusing on customer-centric approaches that account for diverse user needs. Emphasizing research and development in both short-term and long-term preventive measures can yield significant market dividends.

Leaders must also nurture strategic partnerships with regulatory bodies and technology innovators to enhance distribution through both traditional and digital sales channels. This dual-channel approach not only broadens market reach but also reinforces supply chain resilience. Additionally, companies should prioritize market education initiatives and targeted communications strategies that demystify product features for end-users. By aligning product development closely with evolving consumer preferences and regulatory mandates, businesses can cultivate enhanced brand loyalty and drive sustained growth. Ultimately, proactive engagement with emerging market trends and thoughtful segmentation strategies will ensure that industry leaders remain positioned at the forefront of this evolving landscape.

Conclusion and Forward-Looking Perspective

A comprehensive review of the contraceptive market reveals a dynamic and rapidly evolving sector, characterized by transformative shifts in technology, consumer behavior, and regional demands. The evolving landscape, driven by innovations and strategic segmentation, underscores the need for an agile approach to market dynamics. Companies that invest in both product innovation and nuanced customer engagement strategies are best positioned to thrive in this competitive environment.

The robust analysis of market segmentation-from type and formulation to mode of action and distribution channels-demonstrates the critical role that tailored strategies play in addressing the diverse needs of a global consumer base. Trends across regions, including the Americas, Europe, the Middle East, Africa, and Asia-Pacific, highlight the varied challenges and opportunities that require localized strategies alongside global best practices. The collective insights serve as a call for industry stakeholders to embrace an iterative process of innovation, compliance, and proactive market repositioning, ensuring sustainable growth in a technology-driven era. In essence, the current market outlook offers a fertile ground for forward-thinking strategies that anticipate future shifts while addressing today's challenges.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing consumer awareness and education around reproductive health and contraceptives
    • 5.1.1.2. Government initiatives and policies promoting the use of contraceptives for population management
    • 5.1.1.3. Technological advancements leading to the development of newer and more effective contraceptive methods
  • 5.1.2. Restraints
    • 5.1.2.1. Barriers encountered in educating and raising awareness around effective contraceptive methods
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased telemedicine facilitates prescription contraceptive accessibility for remote and busy consumers
    • 5.1.3.2. Growing focus on male contraceptives creating new opportunities for product innovation and diversification
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns of personalization and customization in contraceptive solutions to meet diverse needs
    • 5.1.4.2. Addressing societal and cultural stigmas impacting the acceptance and adoption of contraceptives
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type : High inclination toward oral contraceptives due to their efficacy and ease of discontinuation
  • 5.2.2. End-User : Significant adoption of female contraceptives due to availability of a wide range of products
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Contraceptive Market, by Type

• 6.1. Introduction
• 6.2. Emergency Contraceptives
  • 6.2.1. IUDs
  • 6.2.2. Pills
• 6.3. Hormonal
  • 6.3.1. Implantable Contraceptives
  • 6.3.2. Injectable Contraceptives
  • 6.3.3. Oral Contraceptives
  • 6.3.4. Transdermal Contraceptives
• 6.4. Non-Hormonal
  • 6.4.1. Barrier Methods
  • 6.4.2. Herbal Contraceptives
    • 6.4.2.1. Ayurvedic
    • 6.4.2.2. Homeopathic
  • 6.4.3. Natural Methods
• 6.5. Permanent
  • 6.5.1. Tubal Ligation
  • 6.5.2. Vasectomy

7. Contraceptive Market, by Formulation

• 7.1. Introduction
• 7.2. Patch
• 7.3. Pill
  • 7.3.1. Monophasic
  • 7.3.2. Multiphasic
• 7.4. Ring

8. Contraceptive Market, by Mode Of Action

• 8.1. Introduction
• 8.2. Prevent Implantation
• 8.3. Spermicidal Action
• 8.4. Suppress Ovulation

9. Contraceptive Market, by Material Type

• 9.1. Introduction
• 9.2. Latex-Based
• 9.3. Non-Latex
  • 9.3.1. Nitrile
  • 9.3.2. Polyisoprene
  • 9.3.3. Polyurethane

10. Contraceptive Market, by Duration

• 10.1. Introduction
• 10.2. Long-Term
• 10.3. Short-Term

11. Contraceptive Market, by Usage Frequency

• 11.1. Introduction
• 11.2. On-Demand
• 11.3. Regular Use

12. Contraceptive Market, by Sales Channel

• 12.1. Introduction
• 12.2. Offline
  • 12.2.1. Hospital Pharmacy
  • 12.2.2. Pharmacy
• 12.3. Online
  • 12.3.1. E-Commerce Platforms
  • 12.3.2. Online Pharmacy

13. Contraceptive Market, by Application

• 13.1. Introduction
• 13.2. General Use
• 13.3. Post-Coital Use

14. Contraceptive Market, by End-User

• 14.1. Introduction
• 14.2. Female
  • 14.2.1. Adolescent
  • 14.2.2. Adult
  • 14.2.3. Post-Menopausal
• 14.3. Male

15. Americas Contraceptive Market

• 15.1. Introduction
• 15.2. Argentina
• 15.3. Brazil
• 15.4. Canada
• 15.5. Mexico
• 15.6. United States

16. Asia-Pacific Contraceptive Market

• 16.1. Introduction
• 16.2. Australia
• 16.3. China
• 16.4. India
• 16.5. Indonesia
• 16.6. Japan
• 16.7. Malaysia
• 16.8. Philippines
• 16.9. Singapore
• 16.10. South Korea
• 16.11. Taiwan
• 16.12. Thailand
• 16.13. Vietnam

17. Europe, Middle East & Africa Contraceptive Market

• 17.1. Introduction
• 17.2. Denmark
• 17.3. Egypt
• 17.4. Finland
• 17.5. France
• 17.6. Germany
• 17.7. Israel
• 17.8. Italy
• 17.9. Netherlands
• 17.10. Nigeria
• 17.11. Norway
• 17.12. Poland
• 17.13. Qatar
• 17.14. Russia
• 17.15. Saudi Arabia
• 17.16. South Africa
• 17.17. Spain
• 17.18. Sweden
• 17.19. Switzerland
• 17.20. Turkey
• 17.21. United Arab Emirates
• 17.22. United Kingdom

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Scenario Analysis
  • 18.3.1. Agile Therapeutics acquisition by Insud Pharma to enhance women's health and contraceptive portfolio
  • 18.3.2. Evofem enhances contraceptive innovation through new Phexxi patent and strategic Aditxt merger
  • 18.3.3. Opill and WNBA collaborates to enhance contraceptive access and women's health equity
  • 18.3.4. Bayer and Dare Bioscience collaborates to innovate Hormone-Free contraceptives
  • 18.3.5. Richmond Biotech Company to buy Contraceptive biz for USD 100 Million
  • 18.3.6. UK Launches First Trial of Hormone-free Male Birth Control pill
  • 18.3.7. Aditxt Acquires Phexxi Contraceptive Gel-Maker Evofem for USD 100 million
  • 18.3.8. Dare Bioscience Launches Phase III Hormone-free Contraceptive Trial
  • 18.3.9. Lupin Launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the United States
  • 18.3.10. Bayer and CrossBay Medical to Develop Novel Intrauterine System Inserter
  • 18.3.11. Xiromed LLC Announces Launch of EnilloRing in the United States
  • 18.3.12. Bayer Invests in USD 267.2 Million new Production Facility in Finland to Accelerate Global Access to Modern Contraception
  • 18.3.13. NIH Center Grant Bolsters Male Contraceptive Research
  • 18.3.14. Gates Foundation, Children's Investment Fund Foundation, Pfizer and BD Company Expand Partnership for Greater Access to Injectable Contraceptive for Women
  • 18.3.15. Perrigo Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive
  • 18.3.16. FDA Approves First Nonprescription Daily Oral Contraceptive
  • 18.3.17. Sirona Acquires India's First Vegan Condom Brand Bleu
• 18.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie Inc.
• 2. Acme Generics Pvt. Ltd.
• 3. Afaxys, Inc.
• 4. Agile Therapeutics, Inc.
• 5. Amneal Pharmaceuticals LLC
• 6. ASKA Pharmaceutical Co., Ltd.
• 7. Aurobindo Pharma Limited
• 8. Bayer AG
• 9. Church & Dwight Co., Inc.
• 10. Cipla Limited
• 11. HLL Lifecare Limited
• 12. Insud Pharma, S.L.
• 13. Johnson & Johnson Services, Inc.
• 14. Lupin Limited
• 15. Mayne Pharma Group Limited
• 16. Merck & Co., Inc.
• 17. Mithra Pharmaceuticals S.A.
• 18. Okamoto Industries, Inc.
• 19. Organon & Co.
• 20. Perrigo Company PLC
• 21. Pfizer Inc.
• 22. Piramal Pharma Ltd.
• 23. Reckitt Benckiser Group PLC
• 24. Ritex GmbH
• 25. Sanofi S.A.
• 26. Say It With A Condom, LLC
• 27. Syzygy Healthcare Solutions LLC
• 28. Teva Pharmaceutical Industries Ltd.
• 29. TherapeuticsMD, Inc.
• 30. TTK Healthcare Limited
• 31. Veru Inc.
• 32. Viatris Inc.